Vascular Solutions' thrombus extractor:
This article was originally published in Clinica
Executive Summary
Vascular Solutions has received US FDA 510(k) clearance to sell a version of its Pronto extraction catheter that is sufficiently large but also short enough to remove thrombus from haemodialysis grafts and fistulas. The Pronto-Short device will be used to treat the relatively large-sized grafts and fistulas, which are prone to clotting, with patients requiring on average one de-clot procedure each year, according to the Minneapolis, Minnesota firm. The original Pronto device is designed to remove thrombi from arteries. The firm estimates the additional US market opportunity addressed by the Pronto-Short to be around $100m annually.
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.